Pharmacokinetic evaluation of ambrisentan

被引：15

作者：

Buckley, Mitchell S. ^{[2
]}

Wicks, Laura M. ^{[2
]}

Staib, Robin L. ^{[2
]}

Kirejczyk, Anna K. ^{[2
]}

Varker, Andrew S. ^{[2
]}

Gibson, Jamie J. ^{[3
,4
]}

Feldman, Jeremy P. ^{[1
]}

机构：

[1] Arizona Pulm Specialists Ltd, Phoenix, AZ 85012 USA

[2] Banner Good Samaritan Med Ctr, Dept Pharm, Phoenix, AZ 85006 USA

[3] St Josephs Hosp, Phoenix, AZ 85013 USA

[4] Med Ctr, Dept Pharm, Phoenix, AZ 85013 USA

来源：

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY | 2011年 / 7卷 / 03期

关键词：

PULMONARY ARTERIAL-HYPERTENSION; ENDOTHELIN RECEPTOR ANTAGONISTS; BOSENTAN THERAPY; DOUBLE-BLIND; INHALED ILOPROST; OPEN-LABEL; COMBINATION; SILDENAFIL; SITAXSENTAN; MULTICENTER;

D O I：

10.1517/17425255.2011.557181

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Areas covered: This review focuses on, and critically appraises, the clinical efficacy and safety of ambrisentan as well as its pharmacokinetic and pharmacodynamic properties. The article also gives an expert perspective on the role of ambrisentan in the management of PAH. Expert opinion: Ambrisentan is an effective and safe treatment which is, in the authors' opinion, a valuable addition to the armamentarium against PAH. Ambrisentan offers a relative lack of drug interactions, once daily dosing and reassuring liver safety, offering safety and convenience advantages over bosentan. Presently, there is a lack of comparative studies between PDE5 inhibitors and endothelin receptor antagonists and a lack of data comparing bosentan with ambrisentan. This is hindering data-based conclusions regarding relative efficacy and further studies are needed to define the role of ambrisentan in the management of PAH.

引用

页码：371 / 380

页数：10

共 54 条

[21] Sildenafil citrate therapy for pulmonary arterial hypertension [J].

Galiè, N ;

Ghofrani, HA ;

Torbicki, A ;

Barst, RJ ;

Rubin, LJ ;

Badesch, D ;

Fleming, T ;

Parpia, T ;

Burgess, G ;

Branzi, A ;

Grimminger, F ;

Kurzyna, M ;

Simonneau, G .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (20) :2148-2157

[22] Ambrisentan for the treatment of pulmonary arterial hypertension -: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 [J].

Galie, Nazzareno ;

Olschewski, Horst ;

Oudiz, Ronald J. ;

Torres, Fernando ;

Frost, Adaani ;

Ghofrani, Hossein A. ;

Badesch, David B. ;

McGoon, Michael D. ;

McLaughlin, Vallerie V. ;

Roecker, Ellen B. ;

Gerber, Michael J. ;

Dufton, Christopher ;

Wiens, Brian L. ;

Rubin, Lewis J. .

CIRCULATION, 2008, 117 (23) :3010-3019

[23] Bosentan therapy in patients with Eisenmenger syndrome - A multicenter, double-blind, randomized, placebo-controlled study [J].

Galie, Nazzareno ;

Beghetti, Maurice ;

Gatzoulis, Michael A. ;

Granton, John ;

Berger, Rolf M. F. ;

Lauer, Andrea ;

Chiossi, Eleonora ;

Landzberg, Michael .

CIRCULATION, 2006, 114 (01) :48-54

[24]

*GIL SCI INC, 2009, LET AMBR PACK INS

[25] Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension [J].

Hoeper, M. M. ;

Leuchte, H. ;

Halank, M. ;

Wilkens, H. ;

Meyer, F. J. ;

Seyfarth, H. J. ;

Wensel, R. ;

Ripken, F. ;

Bremer, H. ;

Kluge, S. ;

Hoeffken, G. ;

Behr, J. .

EUROPEAN RESPIRATORY JOURNAL, 2006, 28 (04) :691-694

[26] Goal-oriented treatment and combination therapy for pulmonary arterial hypertension [J].

Hoeper, MM ;

Markevych, I ;

Spiekerkoetter, E ;

Welte, T ;

Niedermeyer, J .

EUROPEAN RESPIRATORY JOURNAL, 2005, 26 (05) :858-863

[27] Drug treatment of pulmonary arterial hypertension - Current and future agents [J].

Hoeper, MM .

DRUGS, 2005, 65 (10) :1337-1354

[28] Combination of bosentan with epoprostenol in pulmonary arterial hypertension:: BREATHE-2 [J].

Humbert, M ;

Barst, RJ ;

Robbins, IM ;

Channick, RN ;

Galié, N ;

Boonstra, A ;

Rubin, LJ ;

Horn, EM ;

Manes, A ;

Simonneau, G .

EUROPEAN RESPIRATORY JOURNAL, 2004, 24 (03) :353-359

[29] Cellular and molecular pathobiology of pulmonary arterial hypertension [J].

Humbert, M ;

Morrell, NW ;

Archer, SL ;

Stenmark, KR ;

MacLean, MR ;

Lang, IM ;

Christman, BW ;

Weir, EK ;

Eickelberg, O ;

Voelkel, NF ;

Rabinovitch, M .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (12) :13S-24S

[30] Drug therapy: Treatment of pulmonary arterial hypertension [J].

Humbert, M ;

Sitbon, O ;

Simonneau, G .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (14) :1425-1436

← 1 2 3 4 5 6 →